Osler, Hoskin & Harcourt acted as Canadian counsel to Milestone Pharmaceuticals Inc. in the offering, Cooleyacted as US counsel to the company. Wilmer Cutler Pickering Hale...
Milestone Pharmaceuticals’ $34.5 Million Common Shares Offering
Linden Capital Partners’ Acquisition of Alcresta Therapeutics
Kirkland & Ellis represented Linden Capital Partners, Wilmer Cutler Pickering Hale and Dorr represented Alcresta Therapeutics and Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital. Linden...
BiomX’s Merger with Adaptive Phage Therapeutics
Haynes and Boone is advising BiomX Inc. on the transaction, Cooley is advising Adaptive Phage Therapeutics and Wilmer Cutler Pickering Hale and Dorr is advising the...
MicroStrategy’s $800 Million Convertible Senior Notes Offering
Wilmer Cutler Pickering Hale and Dorr represented MicroStrategy® Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the initial purchasers. MicroStrategy Incorporated...
Siolta Therapeutics’ $12 Million Series C Financing Round
Wilmer Cutler Pickering Hale and Dorr represented Siolta Therapeutics, Inc. in the transaction. Siolta Therapeutics, Inc. announced it has raised $12 million in Series C Preferred...
Astria Therapeutics’ $125 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Astria Therapeutics, Inc., and Cooley advised the underwriters. Astria Therapeutics, Inc. (Astria) (Nasdaq: ATXS) announced it completed its underwritten registered...
State Street Corporation’s $1.5 Billion Depositary Shares Offering
Wilmer Cutler Pickering Hale and Dorr advised State Street Corporation on the offering, and Cravath, Swaine & Moore advised the underwriters. State Street Corporation (“State Street”)...
TechTarget’s Combination with Informa
Wilmer Cutler Pickering Hale and Dorr represented TechTarget, Inc. in the transaction, and Clifford Chance represented Informa PLC. TechTarget, Inc. (NASDAQ: TTGT) and Informa PLC (LSE:...
Dyne Therapeutics’ $345 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc., and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) (“Dyne”) announced the closing of an underwritten public offering...
Solid Biosciences’ $109 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr advised Solid Biosciences Inc. on the deal. Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines...
Voyager Therapeutics’ $100 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced an underwritten public offering...
Kymera Therapeutics’ $316.2 Million Common Stock Offering
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...